Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 834 Views
-
Last post by NHE
-
- 0 Replies
- 2435 Views
-
Last post by frodo
-
- 0 Replies
- 1118 Views
-
Last post by NHE
-
- 1 Replies
- 1113 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1404 Views
-
Last post by frodo
-
- 0 Replies
- 1642 Views
-
Last post by NHE
-
- 0 Replies
- 2176 Views
-
Last post by vesta
-
- 0 Replies
- 1647 Views
-
Last post by frodo
-
- 0 Replies
- 2269 Views
-
Last post by DIM